Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
What does it do?
Thermo Fisher Scientific is essentially the hardware store for scientists. If a researcher at a hospital needs a machine to analyze blood samples, or a pharmaceutical company needs chemicals to develop a new drug, they likely buy it from Thermo Fisher. The company sells everything from lab fridges and microscopes to the tiny plastic tubes scientists use every day. Think of them as Amazon for the science world — if you work in a lab, almost everything you touch probably came from Thermo Fisher.
Thermo Fisher sits at the center of two massive trends: the boom in new drug development (especially weight-loss drugs and cancer treatments) and the ongoing expansion of biotech research globally. Every time a pharmaceutical company wins a big contract or a government funds new health research, Thermo Fisher benefits because those scientists need supplies and equipment to do their work. After COVID put a spotlight on the diagnostics industry, investors now see Thermo Fisher as a toll road — collecting fees no matter which drug or therapy ends up winning.
How does it make money?
Thermo Fisher makes money across four business lines. Its largest segment, Laboratory Products and Biopharma Services, essentially acts as a supply chain partner for drug companies — think warehousing, manufacturing support, and bulk supplies. Life Sciences Solutions sells the reagents (chemical ingredients) and tools used in cutting-edge research like gene editing. Analytical Instruments sells high-precision lab machines, and Specialty Diagnostics covers clinical testing kits. Total revenue hit $44.6 billion in the latest year, up from $42.9 billion the prior year, with net income of $6.7 billion.
Why do investors care?
The long-term growth story rests on the idea that global spending on healthcare and drug discovery is only going one direction — up. Thermo Fisher has been a disciplined acquirer, buying companies like PPD (a clinical research firm) to expand into higher-margin services. For the thesis to work, biopharma customers need to keep spending on research, Thermo Fisher needs to keep winning outsourcing contracts from drug companies, and emerging markets like China and India need to keep building out their own research infrastructure.
Deep Dive
MemberA full investor briefing on Thermo Fisher Scientific Inc. — history, leadership, risks, and outlook.